Rapid Decay of IgA and IgM Following COVID-19 Infection
Study authors measured the levels of immunoglobulin M, IgG, and IgA in healthcare workers, and observed fast decay of 2 antibodies which has implications for further seroprevalence studies.
Emerging Diseases
Does Fluvoxamine Prevent Clinical Deterioration in Mild COVID-19?
Investigators determined whether fluvoxamine prevents clinical deterioration and decreases severity of disease in patients with mild COVID-19 illness.
Obstructive Sleep Apnea During the COVID-19 Pandemic: Increased Mortality Risk and Viral Spread
Researchers reviewed COVID-19 literature to determine the relationship between obstructive sleep apnea (OSA) and adverse COVID-19 outcomes.
Rate of Severe GI Complications Found to Be Low in Patients Hospitalized With COVID-19
Investigators assessed the rate of severe gastrointestinal complications in patients hospitalized with COVID-19 across 36 medical centers in the United States and Canada.
Expert Roundtable: Physician Burnout During COVID-19
Monisha Sharma, PhD, and Charlene Dewey, MD, provide insight into the current landscape that leads to physician burnout and the next steps to combat it.
Use of Empiric Therapeutic Anticoagulation in Critically Ill Patients With COVID-19
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
Risk for COVID-19 Infection Increased With Common Cancers
Patients with 13 common cancer types have a significantly increased risk for COVID-19 infection and significantly worse outcomes.
ChAdOx1 nCoV-19 Vaccine Promising Against SARS-CoV-2 in Older Adults
AstraZeneca assessed the immunogenicity, safety, and efficacy of their novel chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1 nCoV-19.
Use of Convalescent Plasma Therapy in Severe COVID-19 in the Yale-New Haven Health System
A multicenter team reported on the administration of COVID-19 convalescent plasma to patients with severe COVID-19 in the Yale-New Haven Health System.
β-Coronaviruses Use Lysosomal Organelles for Egress, Suggesting New Therapeutic Pathways
One reason for the lack of antiviral therapies for COVID-19 is the paucity of knowledge about the β-Coronavirus-host cell interface, until now.
-
Loading...
-
Loading...
Next post in COVID19
